NDEs from future AD patients contained longitudinally elevated mean levels of pT181 Tau and pT231 Tau in comparison with controls, whereas t-Tau and, surprisingly, Aβ1–42 remained unaltered. This evidence concerns the gene MAPT and Alzheimer disease.